Vmbook Online ordering

Athersys Inc

ATHX is the stock ticker symbol for a company called Athersys, Inc., which is a biotechnology company based in the United States. The company is focused on the research and development of multi-stem cell therapies, which have the potential to treat a range of medical conditions, including damage to the brain and spinal cord, as well as conditions related to inflammation and immune function.

In terms of financials, Athersys reported a net loss of $15.3 million for the quarter ended September 30, 2021, compared to a net loss of $12.5 million for the same period in 2020. The company's revenue for the first nine months of 2021 was $2.5 million, compared to $0.6 million for the same period in 2020.

Athersys's revenue is primarily derived from collaborations and research and development agreements with other companies. The company has not yet brought any products to market, and therefore does not have any product sales.

In terms of growth, Athersys has been investing in the development of its multi-stem cell therapies, including its lead product candidate, MultiStem, which has shown promise in clinical trials for the treatment of ischemic stroke and other conditions. However, the company has faced several setbacks in the development of MultiStem, including the termination of a partnership with Healios K.K. in Japan.

Overall, Athersys is a speculative biotechnology company that is focused on the development of promising but unproven therapies. While the company has the potential for significant growth if its therapies are successful, it also faces significant risks and uncertainties, including the challenges of developing and commercializing complex biotechnology products.